AI Engines For more Details: Perplexity Kagi Labs You
Gallstone Formation: Cholic acid and other bile acids can contribute to the formation of gallstones when bile becomes supersaturated with cholesterol or when there is impaired gallbladder function. Excessive secretion of cholic acid or changes in the composition of bile can lead to the precipitation of cholesterol crystals, which can aggregate and form gallstones in the gallbladder or bile ducts. Gallstones can cause symptoms such as abdominal pain, nausea, vomiting, and jaundice, and may require medical intervention such as dietary modifications, medication, or surgery.
Bile Acid Malabsorption: Disorders of bile acid metabolism, such as bile acid malabsorption (BAM) or bile acid diarrhea (BAD), can lead to excess bile acids in the intestines and gastrointestinal symptoms such as diarrhea, abdominal pain, bloating, and urgency. Bile acid malabsorption may occur secondary to conditions such as Crohn's disease, celiac disease, irritable bowel syndrome (IBS), or following gastrointestinal surgery. Treatment for bile acid malabsorption may include dietary modifications, bile acid sequestrants, or medications to reduce bile acid production.
Liver Disease: Abnormalities in bile acid metabolism or impaired hepatic function can contribute to liver diseases such as cholestasis, liver cirrhosis, or primary biliary cholangitis (PBC). Cholic acid and other bile acids are synthesized in the liver and excreted into bile, so disturbances in bile acid synthesis, secretion, or transport can affect liver function and lead to liver damage or dysfunction. Elevated levels of bile acids in the bloodstream may also contribute to pruritus (itching) in patients with liver disease.
Metabolic Syndrome: Dysregulation of bile acid metabolism has been implicated in metabolic disorders such as obesity, insulin resistance, and dyslipidemia, collectively known as metabolic syndrome. Bile acids play a role in regulating energy metabolism, lipid absorption, and glucose homeostasis through interactions with nuclear receptors such as the farnesoid X receptor (FXR) and the Takeda G-protein receptor 5 (TGR5). Imbalances in bile acid signaling pathways may contribute to metabolic disturbances and increase the risk of cardiovascular disease and type 2 diabetes.
Gastrointestinal Disorders: Changes in bile acid composition or concentrations can influence gastrointestinal motility, mucosal integrity, and microbial ecology in the gut, which may contribute to the pathogenesis of gastrointestinal disorders such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), or colorectal cancer. Bile acids have been implicated in modulating intestinal inflammation, barrier function, and microbial composition, although the precise mechanisms underlying these effects are still under investigation.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 2.6 | 1.2 | 1.17 |
ADHD | 3.4 | 1 | 2.4 |
Age-Related Macular Degeneration and Glaucoma | 0.8 | 0.4 | 1 |
Allergic Rhinitis (Hay Fever) | 0.8 | -0.8 | |
Allergies | 1.4 | 2.4 | -0.71 |
Allergy to milk products | 0.2 | 1.4 | -6 |
Alopecia (Hair Loss) | 2.2 | -2.2 | |
Alzheimer's disease | 5.4 | 1.4 | 2.86 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 2 | -0.67 |
Ankylosing spondylitis | 1.4 | 2.2 | -0.57 |
Anorexia Nervosa | 3.4 | 1.8 | 0.89 |
Asthma | 1 | 0.8 | 0.25 |
Atherosclerosis | 0.2 | 0.2 | |
Atrial fibrillation | 0.6 | 2 | -2.33 |
Autism | 3.8 | 4 | -0.05 |
benign prostatic hyperplasia | 0.4 | 0.4 | |
Bipolar Disorder | 1.4 | 1 | 0.4 |
Brain Trauma | 0.4 | 0.8 | -1 |
Breast Cancer | 0.2 | 0.2 | 0 |
Carcinoma | 1 | 1 | 0 |
Celiac Disease | 2.4 | 0.8 | 2 |
Cerebral Palsy | 1 | 1 | |
Chronic Fatigue Syndrome | 3 | 1 | 2 |
Chronic Kidney Disease | 2.2 | 1.2 | 0.83 |
Chronic Lyme | 0.2 | 0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.8 | 0.5 |
Chronic Urticaria (Hives) | 0.2 | 0.2 | 0 |
Coagulation / Micro clot triggering bacteria | 2 | 0.6 | 2.33 |
Colorectal Cancer | 0.2 | 1.6 | -7 |
Constipation | 0.8 | 1 | -0.25 |
Coronary artery disease | 2.2 | 1.4 | 0.57 |
COVID-19 | 4.8 | 4.2 | 0.14 |
Crohn's Disease | 6.2 | 4.2 | 0.48 |
cystic fibrosis | 0.4 | 0.4 | |
deep vein thrombosis | 1.2 | 1.2 | |
Depression | 4.6 | 4.3 | 0.07 |
Dermatomyositis | 0.8 | 0.4 | 1 |
Eczema | 0.2 | 0.8 | -3 |
Endometriosis | 0.8 | 1.6 | -1 |
Eosinophilic Esophagitis | 1.8 | 1.8 | |
Epilepsy | 1.8 | 2.8 | -0.56 |
erectile dysfunction | 0.2 | 0.8 | -3 |
Fibromyalgia | 1.4 | 2.8 | -1 |
Functional constipation / chronic idiopathic constipation | 1.8 | 2.2 | -0.22 |
gallstone disease (gsd) | 0.2 | 1 | -4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.6 | 1 |
Generalized anxiety disorder | 0.2 | 1.4 | -6 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 1 | 0.2 | 4 |
Gout | 1 | 1.6 | -0.6 |
Graves' disease | 3.8 | 1 | 2.8 |
Halitosis | 0.4 | 0.6 | -0.5 |
Hashimoto's thyroiditis | 0.2 | 2.6 | -12 |
Heart Failure | 0.6 | -0.6 | |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.2 | -0.2 | |
Hidradenitis Suppurativa | 0.8 | 0.8 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.3 | 0.6 | 1.17 |
hypercholesterolemia (High Cholesterol) | 0.6 | -0.6 | |
hyperglycemia | 0.6 | 0.6 | 0 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
hypersomnia | 0.6 | 0.6 | |
hypertension (High Blood Pressure | 2.6 | 0.4 | 5.5 |
Hypothyroidism | 2.4 | 0.2 | 11 |
IgA nephropathy (IgAN) | 0.6 | 1 | -0.67 |
Inflammatory Bowel Disease | 3.2 | 1.4 | 1.29 |
Insomnia | 1.2 | 0.8 | 0.5 |
Intelligence | 1.2 | -1.2 | |
Intracranial aneurysms | 1.4 | -1.4 | |
Irritable Bowel Syndrome | 1.8 | 2.8 | -0.56 |
Juvenile idiopathic arthritis | 0.6 | 0.6 | |
Liver Cirrhosis | 0.6 | 2 | -2.33 |
Long COVID | 7.4 | 5.8 | 0.28 |
Low bone mineral density | 1.4 | 0.4 | 2.5 |
Lung Cancer | 2.8 | 2.8 | |
ME/CFS with IBS | 0.6 | 0.6 | |
ME/CFS without IBS | 0.2 | 0.8 | -3 |
Metabolic Syndrome | 4.8 | 3.8 | 0.26 |
Mood Disorders | 4.8 | 5.9 | -0.23 |
multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
Multiple Sclerosis | 1.8 | 1.8 | 0 |
Multiple system atrophy (MSA) | 0.6 | 0.6 | |
myasthenia gravis | 0.4 | 0.2 | 1 |
Neuropathy (all types) | 2.4 | -2.4 | |
neuropsychiatric disorders (PANDAS, PANS) | 1.4 | 1.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.8 | 1.9 | 0.47 |
Obesity | 4.8 | 4.4 | 0.09 |
obsessive-compulsive disorder | 3.6 | 1 | 2.6 |
Osteoarthritis | 0.6 | 1.2 | -1 |
Osteoporosis | 1.6 | 1.6 | |
pancreatic cancer | 0.2 | -0.2 | |
Parkinson's Disease | 6 | 1.6 | 2.75 |
Polycystic ovary syndrome | 0.2 | 1.6 | -7 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
Premenstrual dysphoric disorder | 0.2 | 0.8 | -3 |
primary biliary cholangitis | 0.2 | 1 | -4 |
Psoriasis | 0.6 | 2.6 | -3.33 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.4 | 5 | -0.47 |
Rosacea | 0.8 | 0.6 | 0.33 |
Schizophrenia | 1.8 | 3.2 | -0.78 |
scoliosis | 1 | -1 | |
sensorineural hearing loss | 0.6 | 0.6 | |
Sjögren syndrome | 1.8 | 1.4 | 0.29 |
Sleep Apnea | 1.2 | 1.8 | -0.5 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.4 | 0.5 |
Stress / posttraumatic stress disorder | 1.8 | 0.6 | 2 |
Systemic Lupus Erythematosus | 4 | 2.6 | 0.54 |
Tic Disorder | 0.2 | 0.2 | 0 |
Tourette syndrome | 0.2 | 0.2 | |
Type 1 Diabetes | 0.6 | 2.4 | -3 |
Type 2 Diabetes | 3.4 | 3.6 | -0.06 |
Ulcerative colitis | 4.6 | 2.8 | 0.64 |
Unhealthy Ageing | 0.8 | 1.4 | -0.75 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.